NCT03314103已完成3 期
A Multi-center, Randomized, Double-blinded, Phase 3 Trial to Evaluate the Efficacy Against Herpes Zoster of a Live Attenuated Varicella-Zoster Virus Vaccine in Adults Over 40 Years of Age
Jiangsu Province Centers for Disease Control and Prevention3 个研究点 分布在 1 个国家目标入组 30,000 人开始时间: 2017年10月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30,000
- 试验地点
- 3
- 主要终点
- The incidence of herpes zoster 30 days after vaccination.
研究概览
简要总结
Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes.Primary infection is manifested as varicella (chickenpox), whereas reactivation of latent VZV results in a localized eruption known as herpes zoster. More than 99.6% of people 40 years of age orolder had evidence of previous VZV infection. This study plans to have 30000 adults 40 years of age or older involoved in a randomized, double-blind, placebo-controlled trial of an investigational live attenuated varicella-zoster virus vaccine. The investigational vaccines are produced by Changchun Changsheng biotechnology co. LTD. The incidence of herpes zoster and the severity, and duration of the associated pain and discomfort were measured after the vaccination. And the safety of the varicella-zoster virus vaccine is also evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy volunteers aged over 40 years (male or female).
- •Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period.
- •Able to understand the content of informed consent and willing to sign the informed consent.
- •Able to complete the diary card independently.
- •For females only (40-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study.
- •Axillary temperature ≤37.0°C.
排除标准
- •Prior history of herpes zoster.
- •Prior history of vaccination with herpes zoster vaccine or chickenpox vaccine.
- •History of allergic disease likely to be exacerbated by any component of the vaccine.
- •Taking immunoglobulins and/or any blood products within the last 3 months or will receive these products during the study period.
- •Taking certain pharmaceuticals to be like salicylate kind, including aspirin, and difluorosalicylic, or going to take these medicine during the study period.
- •Participation in another research study involving receipt of an investigational product in the last 30 days.
- •Prior administration of attenuated vaccine in last 28 days.
- •Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days.
- •History of serious disease and the participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index.
- •Taking immunosuppressive therapy in last 6 months.
- •Any autoimmune disease or immunodeficient state, autoimmune disease or immunodeficient disease.
- •Active tuberculosis patient.
- •Acute or chronic infections at the vaccination day (axillary temperature>37.0°C).
- •Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.
- •Woman who is breast-feeding.
- •Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.
结局指标
主要结局
The incidence of herpes zoster 30 days after vaccination.
时间窗: 30 days-2 years after the vaccination
The incidence of herpes zoster diagnosed in participants 30 days after vaccination.
次要结局
- Occurrence of adverse reactions after the vaccination.(within 30 days after the vaccination)
- The incidence of herpes zoster after vaccination.(within 0 day -2 years after the vaccination)
- The incidence of herpes zoster with severe postherpetic neuralgia (ZBPI scores≥3) 30 days after vaccination.(30 days-2 years after the vaccination)
- The incidence of herpes zoster with postherpetic neuralgia 30 days after vaccination.(30 days-2 years after the vaccination)
- The incidence of herpes zoster with severe pain (ZBPI scores≥3) 30 days after vaccination. Time Frame: 30 days-2 years after the vaccination(The incidence of herpes zoster with severe pain (ZBPI scores≥3) in participants 30 days after vaccination.)
- The incidence of laboratory-confirmed herpes zoster 30 days after vaccination.(30 days-2 years after the vaccination)
- Occurrence of solicited adverse reactions after the vaccination.(within 14 days after the vaccination)
- Geometric mean titre, geometric mean fold increase and four-fold increase rate of serum for antibody responses 30 days post-vaccination.(30 days after the vaccination)
- Geometric mean titre, geometric mean fold increase of serum for antibody responses 12 months post-vaccination.(12 months after the vaccination)
- Geometric mean titre, geometric mean fold increase of serum for antibody responses 6 months post-vaccination.(6 months after the vaccination)
- Geometric mean titre, geometric mean fold increase of serum for antibody responses 24 months post-vaccination.(24 months after the vaccination)
- Occurrence of severe adverse reactions after the vaccination.(within 2 years)
研究者
Fengcai Zhu
Profesor
Jiangsu Province Centers for Disease Control and Prevention
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 YearsHerpes ZosterNCT04072497Shanghai Institute Of Biological Products522
已完成
3 期
Study on Efficacy of Attenuated Zoster Vaccine, LiveHerpes ZosterNCT04334577Changchun BCHT Biotechnology Co.25,000
进行中（未招募）
1 期
Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors - VZV-specific CD4+ T cellsEUCTR2008-007235-40-ATDepartment für Pädiatrie, Medizinische Universität Innsbruck180
已完成
3 期
Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes ZosterHerpes ZosterNCT01327144EMS177
已完成
3 期
Shingles Prevention StudyHerpes ZosterPostherpetic NeuralgiaNCT00007501US Department of Veterans Affairs38,456